Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.19
ALR's Cash-to-Debt is ranked lower than
87% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. ALR: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
ALR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.14 Max: N/A
Current: 0.19
Equity-to-Asset 0.35
ALR's Equity-to-Asset is ranked lower than
77% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ALR: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
ALR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.35 Max: 0.77
Current: 0.35
-0.49
0.77
Interest Coverage 0.24
ALR's Interest Coverage is ranked lower than
99% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. ALR: 0.24 )
Ranked among companies with meaningful Interest Coverage only.
ALR' s Interest Coverage Range Over the Past 10 Years
Min: 0.24  Med: 0.64 Max: 1.37
Current: 0.24
0.24
1.37
Piotroski F-Score: 3
Altman Z-Score: 0.77
Beneish M-Score: -2.69
WACC vs ROIC
2.18%
1.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 1.88
ALR's Operating Margin % is ranked lower than
51% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ALR: 1.88 )
Ranked among companies with meaningful Operating Margin % only.
ALR' s Operating Margin % Range Over the Past 10 Years
Min: -44.13  Med: 3.85 Max: 7.6
Current: 1.88
-44.13
7.6
Net Margin % -1.64
ALR's Net Margin % is ranked lower than
52% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ALR: -1.64 )
Ranked among companies with meaningful Net Margin % only.
ALR' s Net Margin % Range Over the Past 10 Years
Min: -47.2  Med: -2.92 Max: 8.38
Current: -1.64
-47.2
8.38
ROE % -2.95
ALR's ROE % is ranked lower than
52% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. ALR: -2.95 )
Ranked among companies with meaningful ROE % only.
ALR' s ROE % Range Over the Past 10 Years
Min: -34.13  Med: -3.78 Max: 9.33
Current: -2.95
-34.13
9.33
ROA % -0.65
ALR's ROA % is ranked higher than
53% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. ALR: -0.65 )
Ranked among companies with meaningful ROA % only.
ALR' s ROA % Range Over the Past 10 Years
Min: -15.33  Med: -1.1 Max: 3.27
Current: -0.65
-15.33
3.27
ROC (Joel Greenblatt) % 0.94
ALR's ROC (Joel Greenblatt) % is ranked higher than
51% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. ALR: 0.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -169.25  Med: 10.95 Max: 22.61
Current: 0.94
-169.25
22.61
3-Year Revenue Growth Rate -1.00
ALR's 3-Year Revenue Growth Rate is ranked lower than
66% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ALR: -1.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 10.1 Max: 73
Current: -1
-8.6
73
3-Year EBITDA Growth Rate -8.90
ALR's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ALR: -8.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.2  Med: 6.9 Max: 102.9
Current: -8.9
-39.2
102.9
3-Year EPS without NRI Growth Rate -21.60
ALR's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. ALR: -21.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.6  Med: -12.6 Max: 76.1
Current: -21.6
-57.6
76.1
GuruFocus has detected 6 Warning Signs with Alere Inc $ALR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ALR Guru Trades in Q1 2016

Jeremy Grantham 736,344 sh (New)
George Soros 42,800 sh (New)
Mario Gabelli 494,105 sh (+109.87%)
Private Capital 933,725 sh (+0.34%)
Manning & Napier Advisors, Inc Sold Out
Steven Cohen Sold Out
Keeley Asset Management Corp 713,314 sh (-26.02%)
Jim Simons 506,724 sh (-42.31%)
Diamond Hill Capital 1,052,078 sh (-54.38%)
» More
Q2 2016

ALR Guru Trades in Q2 2016

Leucadia National 79,457 sh (New)
First Eagle Investment 766,566 sh (New)
Jeremy Grantham 1,520,100 sh (+106.44%)
Mario Gabelli 528,225 sh (+6.91%)
Diamond Hill Capital 1,074,665 sh (+2.15%)
George Soros Sold Out
Private Capital 849,998 sh (-8.97%)
Jim Simons 408,824 sh (-19.32%)
Keeley Asset Management Corp 520,100 sh (-27.09%)
» More
Q3 2016

ALR Guru Trades in Q3 2016

John Burbank 6,348 sh (New)
Steven Cohen 6,900 sh (New)
Diamond Hill Capital 2,313,104 sh (+115.24%)
First Eagle Investment 1,167,301 sh (+52.28%)
Jim Simons Sold Out
Leucadia National Sold Out
Private Capital 830,928 sh (-2.24%)
Keeley Asset Management Corp 463,995 sh (-10.79%)
Mario Gabelli 436,660 sh (-17.33%)
Jeremy Grantham 391,000 sh (-74.28%)
» More
Q4 2016

ALR Guru Trades in Q4 2016

Joel Greenblatt 123,245 sh (New)
George Soros 5,300 sh (New)
Leucadia National 40,000 sh (New)
Eric Mindich 1,000 sh (New)
Jim Simons 76,000 sh (New)
First Eagle Investment 1,663,161 sh (+42.48%)
Jeremy Grantham 476,484 sh (+21.86%)
Diamond Hill Capital 2,424,257 sh (+4.81%)
John Burbank Sold Out
Steven Cohen Sold Out
Private Capital 759,047 sh (-8.65%)
Mario Gabelli 380,545 sh (-12.85%)
Keeley Asset Management Corp 403,105 sh (-13.12%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB384.283.123 % Conv Perp Pfd Shs Series -B-

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NYSE:CRL, NAS:ICLR, NAS:PRAH, NAS:CPHD, OTCPK:DSRLF, OTCPK:SWTUY, NAS:VWR, OTCPK:CZMWY, NAS:BRKR, NAS:INCR, NAS:PRXL, NAS:EXAS, NAS:NEOG, NYSE:BIO.B, NYSE:PKI, NAS:QGEN, NAS:DXCM, NAS:VREX, NAS:AXDX, NAS:MEDP » details
Traded in other countries:IM5.Germany,
Headquarter Location:USA
Alere Inc enables individuals to take charge of improving their health and quality of life at home. The Company operates in three segments; professional diagnostics, health information solutions and consumer diagnostics.

Alere develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Top Ranked Articles about Alere Inc

Alere Delays Filing for 2nd Year in a Row The company is investigating accounting errors
For the second year in a row, Alere Inc. (NYSE:ALR) has delayed filing its annual financial report with the Securities and Exchange Commission, citing possible accounting errors. Read more...
Alere's Shareholders Approve Merger With Abbott Seventy-seven percent voted 'yes'
Last Friday, 77% of Alere Inc. (NYSE:ALR)'s shareholders approved a merger with Abbott Laboratories (NYSE:ABT). Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 21.55
ALR's Forward PE Ratio is ranked higher than
78% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. ALR: 21.55 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 73.30
ALR's Price-to-Owner-Earnings is ranked lower than
84% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. ALR: 73.30 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.14  Med: 22.41 Max: 2417.22
Current: 73.3
9.14
2417.22
PB Ratio 2.94
ALR's PB Ratio is ranked higher than
70% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ALR: 2.94 )
Ranked among companies with meaningful PB Ratio only.
ALR' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.74 Max: 3.21
Current: 2.94
0.42
3.21
PS Ratio 1.77
ALR's PS Ratio is ranked higher than
82% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ALR: 1.77 )
Ranked among companies with meaningful PS Ratio only.
ALR' s PS Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.42 Max: 3.97
Current: 1.77
0.53
3.97
Price-to-Free-Cash-Flow 29.54
ALR's Price-to-Free-Cash-Flow is ranked lower than
54% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. ALR: 29.54 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.02  Med: 19.7 Max: 112.72
Current: 29.54
7.02
112.72
Price-to-Operating-Cash-Flow 19.61
ALR's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. ALR: 19.61 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.63  Med: 11.88 Max: 116.47
Current: 19.61
4.63
116.47
EV-to-EBIT 732.64
ALR's EV-to-EBIT is ranked lower than
98% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ALR: 732.64 )
Ranked among companies with meaningful EV-to-EBIT only.
ALR' s EV-to-EBIT Range Over the Past 10 Years
Min: -676  Med: 48.6 Max: 825.4
Current: 732.64
-676
825.4
EV-to-EBITDA 21.69
ALR's EV-to-EBITDA is ranked lower than
67% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ALR: 21.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 13.9 Max: 87.3
Current: 21.69
-173.6
87.3
Current Ratio 2.14
ALR's Current Ratio is ranked lower than
57% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ALR: 2.14 )
Ranked among companies with meaningful Current Ratio only.
ALR' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.76 Max: 3.42
Current: 2.14
0.7
3.42
Quick Ratio 1.65
ALR's Quick Ratio is ranked lower than
64% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ALR: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
ALR' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.35 Max: 2.89
Current: 1.65
0.46
2.89
Days Inventory 95.83
ALR's Days Inventory is ranked lower than
57% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. ALR: 95.83 )
Ranked among companies with meaningful Days Inventory only.
ALR' s Days Inventory Range Over the Past 10 Years
Min: 80.21  Med: 92.61 Max: 104.46
Current: 95.83
80.21
104.46
Days Sales Outstanding 65.11
ALR's Days Sales Outstanding is ranked lower than
54% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. ALR: 65.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.28  Med: 67.28 Max: 79.93
Current: 65.11
60.28
79.93
Days Payable 58.14
ALR's Days Payable is ranked higher than
53% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. ALR: 58.14 )
Ranked among companies with meaningful Days Payable only.
ALR' s Days Payable Range Over the Past 10 Years
Min: 45.36  Med: 52.02 Max: 59
Current: 58.14
45.36
59

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.50
ALR's 5-Year Yield-on-Cost % is ranked lower than
87% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. ALR: 0.50 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.5
3-Year Average Share Buyback Ratio -2.20
ALR's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ALR: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.8  Med: -13 Max: 19.3
Current: -2.2
-60.8
19.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.48
ALR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ALR: 1.48 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.17 Max: 6.82
Current: 1.48
0.45
6.82
Price-to-Median-PS-Value 1.25
ALR's Price-to-Median-PS-Value is ranked higher than
51% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ALR: 1.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.96 Max: 2.84
Current: 1.25
0.36
2.84
Earnings Yield (Greenblatt) % 0.14
ALR's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ALR: 0.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 1.7 Max: 3.1
Current: 0.14
0.1
3.1

More Statistics

Revenue (TTM) (Mil) $2,395
EPS (TTM) $ -0.71
Beta-0.67
Short Percentage of Float2.96%
52-Week Range $31.47 - 49.42
Shares Outstanding (Mil)87.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,394 2,422 2,523
EPS ($) 2.43 2.24 2.29
EPS without NRI ($) 2.43 2.24 2.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.80%
Dividends per Share ($) 0.25 0.25
» More Articles for ALR

Headlines

Articles On GuruFocus.com
Alere Launches the Alere™ Malaria Ag P.f, the First-Ever Rapid Test to Screen Malaria Infection in Apr 25 2017 
Stock Options: Covered Call Option Reports for Alere, Freeport-McMoRan, NVIDIA, Snap Inc., and Twitt Apr 18 2017 
Abbott and Alere Amend Terms of Merger Agreement Apr 14 2017 
Alere Achieves FDA Clearance for Alere™ Reader Platform and Alere BinaxNOW® Influenza A & B Card Apr 11 2017 
First Eagle's Investments of the Last 2 Quarters Mar 30 2017 
Alere Delays Filing for 2nd Year in a Row Mar 16 2017 
Abbott Laboratories Announces Quarterly Dividend Dec 09 2016 
Alere's Shareholders Approve Merger With Abbott Oct 23 2016 
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 
Keeley Small Cap Value Fund 1st Quarter Commentary Apr 26 2016 

More From Other Websites
Alere Launches the Alere™ Malaria Ag P.f, the First-Ever Rapid Test to Screen Malaria Infection in... Apr 25 2017
LPC: US healthcare lending rouses from policy-induced sedation Apr 20 2017
Abbott CEO Upbeat Despite Ongoing Merger Headaches Apr 19 2017
Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter Apr 19 2017
Company News for April 18, 2017 Apr 18 2017
Alere (ALR) Shows Strength: Stock Adds 15.9% in Session Apr 18 2017
Why Straight Path Communications, Alere, and MoneyGram International Jumped Today Apr 17 2017
Will Abbott, Alere Make It To Altar In New Merger Deal? Apr 17 2017
Alere Inc. Shares Surge After Renewed Commitment From Abbott Laboratories Apr 17 2017
Alere Stock Surging on Latest Abbott Agreement Apr 17 2017
Abbott and Alere: It's an M&A Miracle Apr 17 2017
[$$] Abbott, Alere Advance Contentious Merger With Reduced Price Apr 14 2017
Abbott agrees to buy Alere at lower price from earlier offer Apr 14 2017
Alere agrees to discounted $5.3B merger with Abbott, ending legal battle Apr 14 2017
Abbott finalizes discounted deal with Alere, ending legal battle Apr 14 2017
Abbott to slash price it will pay for Alere by nearly 9% to about $5.3 billion Apr 14 2017
Abbott and Alere Amend Terms of Merger Agreement Apr 14 2017
Abbott Laboratories to buy Alere for $4.4 bln - FT Apr 14 2017
Abbott Said to Agree to Buy Alere at Lower Price, FT Reports Apr 14 2017
Abbott and Alere Agree to Play Nice With $5.3 Billion Deal Apr 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)